Evidence mapPaperPMID 41913732Full record

ReviewDrug design, development and therapy2026

The Therapeutic Approach and Mechanism of Action of Insulin Eye Drops for the Treatment of Neurotrophic Keratitis.

Isabel Stasik, Eleftherios Chatzimichail, Efstratia Amaxilati, Panagiotis A G Konstas, Nicolas Feltgen, Georgios D Panos, Zisis Gatzioufas

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Isabel Stasik *Department of Ophthalmology, University Hospital Basel, Basel, Switzerland.
Eleftherios Chatzimichail *Department of Ophthalmology, University Hospital Basel, Basel, Switzerland.
Efstratia AmaxilatiFirst Department of Ophthalmology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID 0009-0009-7071-1557
Panagiotis A G KonstasDepartment of Ophthalmology, School of Medicine, University of Ioannina, Ioannina, Greece.
Nicolas FeltgenDepartment of Ophthalmology, University Hospital Basel, Basel, Switzerland.
Georgios D Panos *First Department of Ophthalmology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID 0000-0001-8399-7456
Zisis Gatzioufas *Department of Ophthalmology, University Hospital Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurotrophic keratopathy or keratitis (NK) is a degenerative corneal disorder characterised by reduced corneal sensitivity and impaired epithelial repair, most often associated with trigeminal nerve dysfunction. Topical insulin eye drops have been proposed as a potential adjunctive therapy, but wider clinical adoption is constrained by variability in preparation methods, inconsistent dosing approaches, and the absence of consensus guidance or regulatory approval. Current clinical experience suggests that topical insulin may be well tolerated and could offer therapeutic value in selected NK settings, including difficult-to-manage cases. Nonetheless, the overall evidence base remains limited and heterogeneous, making it challenging to define optimal regimens or confidently position topical insulin within existing treatment pathways. This review includes clinical studies and case reports and highlights the role of TI as a promising, cost-effective and well-tolerated treatment option for neurotrophic keratopathy, especially in refractory cases. This work also illustrates the need for further research to standardise formulation and dosing, establish practical clinical guidance, and clarify the patient populations and disease stages most likely to benefit, as well as the role of topical insulin alongside established interventions.

Indexed as

InsulinKeratitisAnimalsHumansOphthalmic SolutionsInsulinOphthalmic Solutionscorneacorneal healinginsulin eye dropsneurotrophic keratitispersistent epithelial defectstopical insulin

Identifiers

PMID41913732
PMCPMC13033253

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.